United States v. Cockerell

140 F.4th 213
CourtCourt of Appeals for the Fifth Circuit
DecidedJune 5, 2025
Docket24-10687
StatusPublished

This text of 140 F.4th 213 (United States v. Cockerell) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Cockerell, 140 F.4th 213 (5th Cir. 2025).

Opinion

Case: 24-10687 Document: 99-1 Page: 1 Date Filed: 06/05/2025

United States Court of Appeals for the Fifth Circuit ____________ United States Court of Appeals Fifth Circuit

No. 24-10687 FILED June 5, 2025 ____________ Lyle W. Cayce United States of America, Clerk

Plaintiff—Appellee,

versus

Quintan Cockerell,

Defendant—Appellant. ______________________________

Appeal from the United States District Court for the Northern District of Texas USDC No. 3:18-CR-623-7 ______________________________

Before Stewart, Clement, and Willett, Circuit Judges. Carl E. Stewart, Circuit Judge: The compounding pharmacy business yields high profits. These pharmacies formulate topical creams by combining ingredients, which can result in extremely high reimbursements from insurers. Quintan Cockerell was reaping the benefits as a marketer for two such pharmacies, but he was eventually convicted for receiving illegal kickbacks as part of a conspiracy to induce physicians to prescribe highly lucrative prescriptions. On appeal, Cockerell challenges the sufficiency of the evidence underlying his convictions, certain purported misstatements of law by the Case: 24-10687 Document: 99-1 Page: 2 Date Filed: 06/05/2025

No. 24-10687

Government during his trial, and the restitution order imposed at his sentencing. For the reasons that follow, we AFFIRM the district court’s judgment. I In 2013, Xpress Compounding (“Xpress”) opened its doors as a compounding pharmacy that accepted federal insurance programs. 1 One of those programs was TRICARE, which covers the United States military. Xpress’s overriding focus was on formulating creams that would be as lucrative as possible. Pharmacists, physicians, and marketers associated with Xpress were all involved in developing combinations of ingredients that “would bill out the highest and be the most profitable.” And it worked. Between July 2014 and September 2016, TRICARE and other federal insurers paid Xpress more than $59 million in total. Cockerell was one of Xpress’s “top marketers” and was considered part of the pharmacy’s “inner circle.” He became extremely effective at recruiting and maintaining relationships with physicians to prescribe pain creams for Xpress to fill. He was also intimately involved in developing new formulas so that Xpress could bill insurers at increasingly high rates. He would, for example, personally seek out prescriptions for creams formulated by other compounding pharmacies to see if Xpress could make their creams as, or more, expensive. To compensate marketers like Cockerell, Xpress paid “commissions.” Marketers received a percentage of a billed prescription’s revenue when the marketer influenced the physician to issue the

_____________________ 1 Xpress had a sister company called Rxpress that handled private insurance claims. Because Rxpress did not accept federal insurance in relevant part, it is not the focus of Cockerell’s convictions or his appeal.

2 Case: 24-10687 Document: 99-1 Page: 3 Date Filed: 06/05/2025

prescription. Cockerell concealed his receipt of the commissions by having Xpress pay them in the name of his then-wife, who was supposedly an Xpress employee. But while she filled out employment paperwork for Xpress, she had no actual involvement with the pharmacy. Between August 2014 and June 2016, Cockerell’s commissions totaled nearly $2.5 million. To earn their commissions, marketers created relationships with the doctors whom they influenced to write prescriptions. As part of their outreach, they gave physicians “preload[ed]” prescription pads that had been written out in advance with the formulas that Xpress wanted them to prescribe. Marketers also provided financial and other incentives to induce physicians to send prescriptions to Xpress. Marketers, including Cockerell, showered physicians with lavish vacations and expensive dinners to encourage them to continue writing prescriptions for Xpress to fill. They also offered physicians opportunities to participate in “management service organization[s],” which allowed physicians to invest and earn back money from each prescription they wrote. Cockerell specifically used this tactic for prescriptions that were reimbursed by federal insurers like TRICARE, even though doing so is impermissible under their policies. 2 These incentives were crucial to Xpress’s ability to obtain prescriptions. As one marketer later testified, “if we didn’t pay the doctors, we would have had no business.”

_____________________ 2 As Scott Schuster—former co-owner of Xpress and a Government witness— testified, management service organizations and other “vehicles where doctors are invested” are permissible for “private insurance only,” not for federal insurers. James Gogue—a healthcare fraud specialist who was also a Government witness—further explained that TRICARE will not pay for prescriptions if prescribing doctors are “incentiviz[ed] or giv[en] a benefit . . . to influence treating the patient.” Those “benefit[s],” he explained, can “include an investment opportunity,” even one in “a different pharmacy.”

3 Case: 24-10687 Document: 99-1 Page: 4 Date Filed: 06/05/2025

Some marketers, including Cockerell, also recruited other marketers, known as “sub-reps.” Cockerell employed his sub-reps through a shell corporation called QSpine, and he determined what percentage of the Xpress commission the sub-rep would receive, based on the prescriptions that the sub-rep influenced. Cockerell also ensured that he received his cut. He made clear that he was entitled to an “override,” or an additional percentage payable directly to him, on revenue attributed to prescriptions that his sub- reps obtained. In 2015, Dr. Christopher Ince prescribed three topical creams to a patient (“L.L.”) who was insured by TRICARE. Cockerell and Steve Bergman, one of Cockerell’s sub-reps, each took a share of TRICARE’s payments on those claims, with Cockerell earning a 20% “override”—a total of $1,723.53. Due in part to that transaction, Cockerell was later convicted of paying and receiving healthcare kickbacks in violation of 42 U.S.C. § 1320a- 7b(b) (the “Anti-Kickback Statute”); conspiracy to do the same in violation of 18 U.S.C. § 371; and money laundering in violation of 18 U.S.C. § 1957. 3 The district court sentenced Cockerell to 29 months of imprisonment and two years of supervised release. It also ordered him to pay $59,879,871 in restitution. Cockerell then timely filed this appeal, in which he raises three challenges to his conviction and sentence. First, he challenges the sufficiency of the evidence underlying his convictions. Second, he challenges certain purported misstatements of the law by the Government during its closing and

_____________________ 3 Cockerell was also charged with conspiracy to commit money laundering in violation of 18 U.S.C. § 1956(h) and two further counts of substantive money laundering in violation of 18 U.S.C. § 1957. The jury ultimately acquitted him of these charges, and they are not at issue in this appeal.

4 Case: 24-10687 Document: 99-1 Page: 5 Date Filed: 06/05/2025

rebuttal arguments at trial. Third, he challenges the district court’s restitution order. None of his arguments, however, merit reversal.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Miles
360 F.3d 472 (Fifth Circuit, 2004)
United States v. Loeffel
172 F. App'x 612 (Fifth Circuit, 2006)
United States v. Vargas
580 F.3d 274 (Fifth Circuit, 2009)
United States v. W. Borden Strickland
509 F.2d 273 (Fifth Circuit, 1975)
United States v. David Samuel Iredia
866 F.2d 114 (Fifth Circuit, 1989)
United States v. Chol Ku Kang
934 F.2d 621 (Fifth Circuit, 1991)
United States v. Jaime Moreno-Gonzalez
662 F.3d 369 (Fifth Circuit, 2011)
United States v. Jose Escalante-Reyes
689 F.3d 415 (Fifth Circuit, 2012)
United States v. Lia St. Junius
739 F.3d 193 (Fifth Circuit, 2013)
United States v. Raymond Shoemaker
746 F.3d 614 (Fifth Circuit, 2014)
United States v. Arun Sharma
609 F. App'x 797 (Fifth Circuit, 2015)
United States v. Calvin Shelton
694 F. App'x 220 (Fifth Circuit, 2017)
United States v. Warren Dailey
868 F.3d 322 (Fifth Circuit, 2017)
United States v. Sherrie Bennett
874 F.3d 236 (Fifth Circuit, 2017)
United States v. Karl Scott
892 F.3d 791 (Fifth Circuit, 2018)
United States v. Kim Ricard
922 F.3d 639 (Fifth Circuit, 2019)
United States v. Riyaz Mazkouri
945 F.3d 293 (Fifth Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
140 F.4th 213, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-cockerell-ca5-2025.